- Home
- FLC vs FENC Comparison
FLC vs FENC Comparison
Compare FLC & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$7.68
Company Overview
Basic Information| Metric | FLC | FENC |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.5M | 276.3M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | FLC | FENC |
|---|---|---|
| Price | $17.54 | $7.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 37.8K | ★ 183.3K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.62 | $4.68 |
| 52 Week High | $15.45 | $9.92 |
Technical Indicators
Market Signals| Indicator | FLC | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 47.61 |
| Support Level | $17.33 | $7.51 |
| Resistance Level | $17.60 | $8.16 |
| Average True Range (ATR) | 0.15 | 0.33 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 76.67 | 36.24 |
Price Performance
Historical Comparison FLC
FENC
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.